Infection of bone

Ashley Black, Premium Products Built from Recycled MaterialsAshley Black, Net-Zero manufacturing by 2024Ashley Black, Female Owned Ashley Black, Female Run31 curated kits for everything from cellulite to sports recovery, to our facelift facial at up to 80% off HOUSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Ashley Black, inventor of the FasciaBlaster tools, announces 31 days of “My Favorite Things” holiday product specials. The curated series kicked off Dec-1 and will run through Dec 31, 2023. Ashley will showcase her favorite FasciaBlaster tools, how they work and holiday savings up to 80% off throughout the entire month of Dec. “I’ve curated FasciaBlaster kits, by ailment or need, so every issue from tired achy feet, to low back tension, to gorgeous smooth legs, we have something for everyone. The most important thing to me is that we are introducing self-care for regenerating tissue to new users and that’s a game changer.” Access holiday promotions at www.AshleyBlackGuru.com About Ashley Black: Ashley Black is Stevie Award winner, Woman of the Year, Lifetime Achievement in Consumer Goods, and Entrepreneur of the Year. She is the #1 best-selling author of “The Cellulite Myth” and “BE… From Passion and Purpose to Products and Prosperity.” She is best known for her invention of the therapy and beauty tool; the FasciaBlaster®. After suffering from Juvenile Rheumatoid Arthritis, a bone-eating infection, and a total hip replacement, she had no choice but to look for answers that would defy her medical prognosis of a life of pain management and debilitation. She discovered that limitations and pain in her body were due to thickening and scarring of fascia, the connective tissue that connects, penetrates, envelopes, and surrounds every human cell, like soil to plants. This contributed to the creation of a new field of science: Fasciology™. Since 1999 Ashley forged a career as a fascia authority with personal clients in pro sports and Hollywood. The results with her personal clients inspired her to invent the FasciaBlaster® tools in 2014 that have gone on to sell over $170M and amass 9M faithful fans. Her mission in life is to bring evidence-based bio-hacks for reverse aging, increase longevity, and improve health naturally to the mass market. Black owns The Fascia Advancement Academy and is certifying medical and sports professionals in the use of her tools and methodology and partnering with high-end spas and medical facilities to bring her vision to life. With an eco and socially conscious brand, founded and run by women, Ashley couldn't be more thrilled. For more information www.AshleyBlackGuru.com | About Ashley | Our ESG Principles CONTACTS: Communications Contact:Matt BirdCommPro Agency matt@commpro.com *See more sustainable fashion coverage and the original article: https://esgnews.com/ashley-black-announces-31-days-of-my-favorite-things-holiday-specials-up-to-80-off-promotion/ A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de1c593a-19eb-4594-8d3f-03e93cadec1c

Researchers have developed a new surgical implant that has the potential to transform the treatment of complex bone infections. When implanted on an injured or infected bone, the material can not only speed up bone healing, it also reduces the risk of infections without the need for traditional antibiotics.  Researchers at RCSI University of Medicine and Health Sciences and Advanced Materials and Bioengineering Research Centre (AMBER) have developed a new surgical implant that has the potential to transform the treatment of complex bone infections. When implanted on an injured or infected bone, the material can not only speed up bone healing, it also reduces the risk of infections without the need for traditional antibiotics. The newly published paper in the journal Advanced Materials, tackles the complex clinical problem of bone infection, or osteomyelitis, which affects one in around 5,000 people within the US only each year. When a bone is infected, the priority is to heal it quickly. Standard clinical treatment, including several weeks with antibiotics and often removal of the infected portion of bone tissue, can be slow. Already around half of bone infections are caused by MRSA, which is resistant to antibiotics, and prolonged antibiotic treatment pushes up the risk of infections becoming tolerant to the treatments we have at our disposal, making infections harder to control. To help patients to heal well, researchers at RCSI created a material from a substance that is similar to our bones. The scaffold-like structure of this material means that when it is implanted onto injured or diseased bone, it encourages the bone to regrow. In this case, the RCSI researchers infused the scaffold with tiny nanoparticles of copper, which are known to kill the bacterium that causes most bone infections. Furthermore, they also incorporated a specific genetic molecule, an inhibitor of microRNA-138, into the scaffold to stimulate the formation of new bone at the site where the material is implanted. In the study, the researchers describe how preclinical lab tests showed the implanted scaffolds with the copper nanoparticles and microRNA could stimulate bone regrowth in a fortnight, and that the scaffold stopped 80% of potentially harmful bacteria from attaching to the site. They also saw that the implants stimulated a good blood supply to cells on the scaffold which is crucial for the health and viability of the newly formed bone. "Overall, we combined the power of antimicrobial implants and gene therapies, leading to a holistic system which repairs bone and prevents infection," says first author of the study, Dr Joanna Sadowska, a Marie Sklodowska-Curie Postdoctoral Fellow at the RCSI Tissue Engineering Research Group (TERG). "This makes a significant step forward in treating complex bone injuries, and the timescale we saw in our preclinical studies suggest our approach could revolutionise treatment times for patients in the future." Professor of Bioengineering and Regenerative Medicine at RCSI, Prof. Fergal O'Brien, Principal Investigator on the paper and Head of TERG, sees many potential benefits to the implant. "This implant can deliver the antimicrobial treatment directly to the infected bone so it can be a local and targeted approach, as opposed to exposing more of the body to long-term antibiotics," he says. "Add to this that our implant incorporates copper particles that can stop bacteria from establishing an infection at the site and at the same time they stimulate blood vessel formation in bone. The nature of the implant also means that the body can naturally break down the material when the bone heals, so there is no need to remove it surgically." Professor O'Brien, who is Deputy Director of AMBER, the SFI Centre for Advanced Materials and BioEngineering Research, sees the implant as an important future step mode of targeted delivery for more precise and effective treatments of injured and diseased bone. "This is a first-of-its-kind implant that integrates different solutions to encourage bone regrowth and address infections, and the new study is an important step to bringing it towards patients for faster and more effective treatments," he said. The novel nature of this research was recognised earlier this year during the Annual Meeting of the Orthopaedic Research Society, in Dallas, Texas, where Dr Sadowska was awarded a New Investigator Recognition Award for outstanding scientific paper. RCSI researchers collaborated on the study with colleagues from Trinity College Dublin and from Friedrich-Alexander University Erlangen-Nuremberg in Germany. The study was supported by funding through EU Horizon 2020, the European Research Council, the SFI US-Ireland Research and Development Partnership and the The ON Foundation, Switzerland.

RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category A In an ex-vivo burn wound study, R327G showed a 4 to 5-log reduction (>99.99%) against Methicillin-resistant bacteria, Staphylococcus aureus (S. aureus) Clinical trial preparations are underway across multiple unmet medical needs SYDNEY, Australia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to provide an update on the utilization of RECCE® 327 as a gel formulation, or RECCE® 327 Gel (R327G), by a qualified medical practitioner for patients with antibiotic-resistant Gram-positive and Gram-negative bacterial infections under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category A, a compassionate-use provision. “Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “To see Recce making a difference for patients in such great medical need is a significant sign of new hope in the fight against drug-resistant superbugs. We look forward to building upon these successes in present and future clinical trials.” Patients have been treated under the SAS-Category A, a notification pathway that health practitioners can access on behalf of patients who are seriously ill with a condition from which death is likely to occur within a matter of months or from which premature death is expected to occur in the absence of early treatment and does not constitute a clinical trial.1 R327 and R327G are experimental compounds, not market approved for use in humans, with safety and efficacy to be determined by current clinical studies. The results shown below must be considered anecdotal; however, they are presented in the interest of continuous disclosure obligations and are not part of any current clinical trials. Patient Case Study Example A A 70–75-year-old male who received a puncture wound from a metal spike injury was unresponsive to all prior antibiotics, and with the infection spreading, he was preparing for surgical intervention. After 24 hours and only one dosing application of R327G, the infection had clinically responded, with the patient not requiring a wound debridement prior to treatment. Furthermore, the redness and swelling of the wound were reduced, with no reported stinging at any point. At 30 days post-treatment, the wound had successfully healed and closed. Patient Case Study Example B A 72-year-old male with type 2 diabetes, peripheral vascular disease, and peripheral neuropathy was unresponsive to all prior antibiotics. Prior to treatment with R327G, the patient showed significant bacterial infection, redness, and swelling. Upon applying R327G, the initial redness and swelling had minimized after seven days, with the wound healing and drying up. On day 10, the patient showed no signs of infection and pus formation, and the wound continued to heal. On day 14, the wound significantly improved, demonstrating R327G to be well-tolerated. Surgical intervention was averted, such as limb amputation, which is common in patients with diabetes. Other patient case studies have not been disclosed for matters of confidentiality; however, they include the successful treatment of but are not limited to necrotizing fasciitis (flesh-eating disease), osteomyelitis (bone infection), and complex skin structure bacterial infections. Preclinical results support the potential of R327 as a gel formulation An independent clinical research organization conducted an animal study where multiple R327G formulations were tested for efficacy against Methicillin-resistant S. aureus (MRSA), which is listed as “High” on the World Health Organization’s Priority Pathogen list of antibiotic-resistant bacteria, using an ex-vivo porcine (pig) skin model. R327 as an intravenous (IV) formulation, or R327 IV, was also included in this study and is currently being evaluated in human clinical trials. After 24 hours, R327G achieved a 4 to 5-log reduction (99.99% - 99.999% reduction) in all formulations and had the greatest overall efficacy against MRSA. MRSA infections are one of the leading causes of hospital-acquired infections and are commonly associated with significant morbidity, mortality, length of stay, and cost burden.2 MRSA most often causes skin infections and, if left untreated, can become severe and cause sepsis.3 Treatment Log10 Reduction from Control (Mean ± SD) 1hr Control N/A RECCE® 327 I.V. 3.04 ± 1.20 RECCE® 327 Gel (1.0% CMC) 2.10 ± 1.23 RECCE® 327 Gel (2.0% CMC) 0.90 ± 0.13 24hr Control N/A RECCE® 327 I.V. 4.97 ± 0.11 RECCE® 327 Gel (1.0% CMC) 4.32 ± 0.81 RECCE® 327 Gel (2.0% CMC) 5.07 ± 0.26 Numerical values for Methicillin-resistant Staphylococcus aureus Log10 Reduction The Company engaged Linnaeus Bioscience, based in San Diego, CA, to test R327G against antimicrobial activity in different formulations. The image below shows a clearing in a lawn of Escherichia coli (E. coli) (ATCC 25922) on solid LB-agar media. Each of the gel formulations (R327G “a, b, c and d”) produced a zone of clearing approximately 13mm in diameter, indicating each formulation is active and demonstrates similar potency to R327 IV (B0107) on solid media. Monitored dispersion is observed outside the dark ring. G0001 (placebo control) had no effect on the E. coli; however, R327 IV and R327G successfully dispersed outwards through the bacterial lawn. The above topical results may lead to the progression of R327G to Stage 2 investigations with the burn wound team at Fiona Stanley Hospital, including the potential use among patient populations. Separately, clinical trial applications for the topical utilization of R327G in common and complicated skin and soft tissue infections are progressing in line with these developments. About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy. Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs. Corporate Contact James Graham Recce Pharmaceuticals Ltd +61 (02) 9256 2571 James.graham@recce.com.au Media & Investor Relations (AU) Andrew Geddes CityPR +61 (02) 9267 4511 ageddes@citypublicrelations.com.au Media (USA) Jordyn Temperato LifeSci Communications jtemperato@lifescicomms.com Investor Relations (USA & EU) Guillame van Renterghem LifeSci Advisors gvanrenterghem@lifesciadvisors.com 1 2 3 (MRSA),-Related%20Pages&text=Staph%20bacteria%20are%20usually%20harmless,of%20resistance%20to%20some%20antibiotics. Photos accompanying this announcement are available at Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure 3 Clearing in a lawn of Escherichia coli (E. coli) on solid LB-agar media. Table 1 Table 1